The latest price list of the targeted drug capmatinib in 2024

Capmatinib (Capmatinib) is a drug used to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have mutations that cause mesenchymal-to-epithelial transition exon 14 (METex14) skipping, according to a U.S. Food and Drug Administration (FDA)-approved test. It is available in tablet form, each containing 150 mg or 200 mg of capmatinib.

Capmatinib is a tyrosine kinase inhibitor that acts on tyrosine kinaseMET. MET is an enzyme, a protein that is involved in various cellular processes. Its activity is abnormal or increased in cancer, which can lead to uncontrolled growth of cells and the development of tumors. In some cases (3-4% of lung cancer patients), mutations in the MET gene cause exon 14 to be skipped. The jumping in METex14 causes the exons that contain the genetic code for making proteins to not fit together correctly. Capmatinib binds to and inhibits MET. Tumor cells with hyperactive MET activity will be most affected, leading to tumor cell death and cessation of cancer growth.

At present, the original drug capmatinib has just been approved for marketing in China, and its price and medical insurance related matters are not yet available; the original capmatinib sold in Hong Kong has a specification of200mg*60 and the price per box is more than 30,000 yuan. The European version of the original drug sold overseas, specifications200mg*120, is priced at more than 50,000 yuan per box (the price may fluctuate due to exchange rates), the price is relatively expensive. In addition, cheaper generic drugs of capmatinib are also sold overseas, and their drug ingredients are basically the same as the original drug. For example, the price of 20 mg*56 tablets produced by relevant pharmaceutical factories in Laos is more than 3,000 yuan per box (the price may fluctuate due to exchange rates).